MOA
Rituxan selectively targets only CD20+ B cells2—not the entire immune system
CD20 is not found on stem cells, pro-B cells, normal plasma cells, or other normal tissues2

B-cells are believed to contribute to the immune processes that lead to inflammation and joint damage2

Potential roles of the immune process in the pathogenesis of RA
B cells are implicated in the production of cytokines16
- IL-1, TNF, IL-6
Osteoclast activity and bone erosion
- In some models, IL-1, TNF, and IL-6, as well as other factors, enhance RANKL
- RANKL mediates osteoclastogenesis

